Based on the Harvard Bioscience Inc stock forecast from 0 analysts, the average analyst target price for Harvard Bioscience Inc is not available over the next 12 months. Harvard Bioscience Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Harvard Bioscience Inc is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Harvard Bioscience Inc’s stock price was USD 1.33. Harvard Bioscience Inc’s stock price has changed by -10.14% over the past week, -32.83% over the past month and -69.50% over the last year.
No recent analyst target price found for Harvard Bioscience Inc
No recent average analyst rating found for Harvard Bioscience Inc
Company Overview Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts. Read Less
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump pro...Read More
Frequently Asked Questions About Harvard Bioscience Inc (HBIO) Stock
Stock Target Advisor's fundamental analysis for Harvard Bioscience Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on HBIO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on HBIO's stock to indicate what its average analyst target is.
HBIO stock's Price/Earning ratio is 147.50.
Our analysis grades HBIO stock's Price / Earning ratio at F. This means that HBIO stock's Price/Earning ratio is above 85% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this HBIO may be a overvalued for its sector.
The last closing price of HBIO's stock was USD 1.33.
The most recent market capitalization for HBIO is USD 0.08B.
Unfortunately we do not have enough analyst data on HBIO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Harvard Bioscience Inc's stock.
As per our most recent records Harvard Bioscience Inc has 391 Employees.
Harvard Bioscience Inc's registered address is 84 October Hill Road, Holliston, MA, United States, 01746.
You can get more information about it from Harvard Bioscience Inc's website at https://www.harvardbioscience.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Harvard Bioscience Inc (HBIO) Stock
Stock Target Advisor's fundamental analysis for Harvard Bioscience Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on HBIO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on HBIO's stock to indicate what its average analyst target is.
HBIO stock's Price/Earning ratio is 147.50.
Our analysis grades HBIO stock's Price / Earning ratio at F. This means that HBIO stock's Price/Earning ratio is above 85% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this HBIO may be a overvalued for its sector.
The last closing price of HBIO's stock was USD 1.33.
The most recent market capitalization for HBIO is USD 0.08B.
Unfortunately we do not have enough analyst data on HBIO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Harvard Bioscience Inc's stock.
As per our most recent records Harvard Bioscience Inc has 391 Employees.
Harvard Bioscience Inc's registered address is 84 October Hill Road, Holliston, MA, United States, 01746.
You can get more information about it from Harvard Bioscience Inc's website at https://www.harvardbioscience.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HBIO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
